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1. Introduction
Current research focuses on the development of new agents
and the assessment of combination of therapies and integra-
tion of the new agents.
In this context, it becomes critically important to identify
potential biological targets, the blockade ofwhichwould affect
multiple downstream signaling cascades.
2. Blocking the EGFR pathway and
radiotherapy
One of the most attractive pathways is the inhibition of
the epidermal growth factor receptor (EGFR) signaling path-
way, either through small molecules (geﬁtinib or erlotinib) or
monoclonal antibodies (cetuximab), combined with radiothe-
rapy. Few data exist in direct clinical results on the association
between Tyrosine Kinase Inhibitors (TKIs) and radiotherapy,
but data do exist that in vitro TKIs reinforce chemotherapy and
radiation.
Cetuximab is a chimeric human–mouse monoclonal anti-
body that binds to the EGFR and inhibits the growth of
EGFR-expressing cancer cell lines in vitro and in vivo in athymic
nude mice. Radiation activates EGFR signaling, which leads
to radio-resistance by inducing cell proliferation and enhanc-
ing DNA repair and synergistic activity when cetuximab was
combined with radiotherapy. NSCLC cell lines1 treated with
cetuximabaloneor in combinationwith radiation, chemother-
apy or chemoradiation to determine the cooperative effects
of cetuximab both in vitro and in vivo in athymic nude mice
bearing NSCLC xenografts. Cetuximab could be beneﬁcial for
some patients and detrimental to others and that cetuximab
sensitivity does not correlate clearly with EGFR expression
levels, though it appears to need some degree of EFGR expres-
sion. However, studies are needed to establish proper safety
for this therapy approach in patients with locally advanced
lung cancer. Up to now, the most impressive results have
been those achieved by the Radiation TherapyOncologyGroup
study (RTOG 0324).2 Two-year follow-up reported median sur-
vival of 22.7 months and overall survival of 49.3%, better than
any study previously reported by the RTOG.
Geﬁtinib has a radiosensitizing effect that was conﬁrmed
in cell lines.3 Stinchcombe and colleagues investigated the
tolerance of Geﬁtinib for unresectable stage III NSCLC in
combination with radiotherapy. The primary toxicities of
concurrent high-dose three-dimensional conformal thoracic
radiotherapy were grade 3 esophagitis (19.5%) and cardiac
arrhythmia (9.5%), but survival results were disappointing,
with overall survival at 9 months.4
Evidence of treatmentwith erlotinib and thoracic radiothe-
rapy is less than with geﬁtinib. In short, results have not been
very encouraging, though there was no excess toxicity. The
phase I study5 by Choong aimed to determine the maximum
tolerated dose of erlotinib administered with two standard
chemo-radiotherapy regimens for non-small-cell lung can-
cer, but median survival times were disappointing. Epidermal
growth factor receptor IHC or FISH-positive patients showed
no signiﬁcant overall survival difference.
3. Antiangiogenic and radiotherapy
Tumor cells produce growth factors that stimulate prolif-
eration and migration of endothelial cells, and ﬁnally the
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formation of new blood vessels within the tumor tissue.
Radiation induces cell death as a result of damage to cell
membranes, DNA and microvascular endothelial cells within
the tumor stroma. In response to the endothelial damage
and hypoxia, tumor cells increase their expression of proan-
giogenic growth factors, such as vascular endothelial growth
factor (VEGF) and ﬁbroblast growth factor.
Therefore, it is reasonable to think that a combination of
antiangiogenic therapy and radiotherapy may improve tumor
control. However, one must step carefully on transferring
the conclusions of treatments in tumor xenograft models to
patients, as even gene expression may vary, depending on the
location of the grafted tumor. In vitro clonogenic cell-survival
studies of H441 lung adenocarcinoma cells, ZD6474 treatment
impaired the efﬁciency of the repair of sub-lethal radiation
damage, even after short-term exposure of lung cancer cells
to ZD6474.
There are few studies of bevacizumab with thoracic radio-
therapy. The data we have from reported studies advise
caution and use always of controlled clinical trials. Selection
of patients is essential to avoid potentially mortal toxicity.6
3.1. m-TOR pathway
TheRas/PI3 kinasepathwaywithAkt is anattractive target.We
know that this pathway is frequently activated by mutation of
Ras or components of the pathway, and by deregulated growth
factor receptor signaling to Ras. Activation of Ras signaling
increases the survival of tumor cells exposed to agents that
cause DNA damage. Inhibition of oncogenic Ras expression
also decreases radiation survival in both cell lines to a simi-
lar degree contribute to radiation survival when activated by
oncogenic mutations.
mTOR inhibition interrupts the radiation-induced stress
response of tumor cells that should protect tumor microvas-
culature against radiation damage. In tumor cells, mTOR
inhibition prevents radiation-induced expression of proangio-
genic growth factors such as VEGF, reducing the angiogenic
potential of tumor cells themselves. In endothelial cells,mTOR
blockade disrupts the VEGF signaling pathway, leading to inhi-
bition of endothelial cell proliferation.
mTOR is an attractive target in cancer therapy because
the PI3K/Akt/mTOR pathway is frequently activated in tumors
promoting cell proliferation and radiation resistance. Genetic
variations in this pathway may modulate clinical out-
comes and be used to build a model of individualized
therapy.
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